RE:RE:RE:RE:RE:We need a large US based marketing firm!!!I'll trade 55+ for Bill Gates. Come on I've been here longer than most on here and probably one of the largest shareholders as well. I'm just saying they could do a much better job of marketing. It's been a solid growth year no doubt but now is the time to turn it on. Hire some professional PR firms and yell it from the rooftops. Not everyone is an expert at all aspects of business. Tripp needs to acknoweldge that the marketing piece has been wanting and now is not the time to continue on the same path.
Jonnyboy85 wrote: Does grail have 55+ partners? And an active revenue stream? Lol
LithLover wrote: Come on Jonny you have to admit the marketing hasn't been even comparable to Grail, Exas or others. Time to play with the big boys
Jonnyboy85 wrote: You guys are forgetting that we've already done the biggest marketing campaign we've ever accomplished through our partnerships for covid testing. 55+ new partners over the last year and every single one of them I'm sure have got the full court press for Aristotle. At the hight of our popularity we are announcing to the world our legitimacy in global medical diagnostics, recording quarterly revenue and launching Aristotle the world's first high accuracy multi cancer panel diagnostic.
capebretongirl wrote: LithLover wrote: I would like to see the company hire a large US marketing company or PR firm. No offense to Rebecca but her IR firm does not appear very big and she may be great at helping nagivate news releases it doesn't appear any new large marketing initiatives have happened. Certainly not impressed with her website:
https://www.fighouse.ca/ "Some of the companies we have worked with are: Magor Communications, Allied Gold Ltd., Serabi Gold, Mobility Communications, Luna Gold, Perseus Mining Limited, PMI Gold Corp., and Fission Energy"
I'm sure she's very good with Canadian Energy/Mining companies but can she help with this once in a company's history launch?
I'm very excited we have the $7 million in the war chest. Tripp needs to work on his board connections that Harry and Rory have, hire a US marketing firm and get the message out.
Pretty disappointed to see only 501 followers and 15 likes on a LinedIn post. Or 533 views on a youtube video.
It's obvious to me that Stagezero needs to increase exposure and develop it's brand prior to launching Aristotle. This is what I was talking about with momentum. News releases and updates provide word of mouth, more eyes on the stock and than your launch starts off with an even larger base. If Tripp isn't going to do that than hire a proper marketing firm that will.
I need to add to my post of the dream the other day.
1) Tripp announces engagement of a large PR/marketing firm in the US
2) Tripp halts the stock and news comes out that an agreement has been made or letter of understanding from Blue Cross/Blue Shield that they have approved the test for their members.
3) A week later Tripp halts and announces Aristotle is fully commercialized and avaiable to all
4) Tripp announces a national deal with numerous first responders/fire fighter associations to be tested
5) Tripp announces medicare/medicaid and others will fully fund the test
Yes, this has been the misfortune for SZ over the past couple of years and the reason for Colonsentry's failure - read: no one really knows what SZLS is. Social media is wonderful and gets the word out there to a limited extent - however if the aspiration is to become a multi billion dollar company then we need more than 500 followers on the Linkedin, Facebook or investor tel videos. We have all read about the pent up demand for cancer detection thru the pandemic and the opportunity that exists today - I read yesterday where approx 22 million may have been affected as they were afraid to go to hospitals for testing purposes because of the covid risk. Imagine yourself as one of those 22 million fearful cancer candidates - they google cancer detection tests and come up with a multitude of hospitals, cancer/treatment centres and clinics in major centres, but where is Stage Zero and its liquid biopsy test?? This potential client then goes on to follow up with whatever is available and probably is in touch with his/her physican for follow up via traditional processes. Where does Stage Zero come into play in this scenario?
So yes - now (actually over the past several months) was/is the time for a publicity campaign via a large US marketing firm to educate the public on Aristotle's arrival. Create google internet links to SZ so cancer detection searches show our name and do whatever is possible to educate the public - this is what PR firms do best. I am hopeful that when Aristolte rolls out that a PR strategy will accompany it at that time - however doing it in advance would be the smarter way and the way to create momentum - certainly we have the funds to accomplish this. Each week we predict an encouraging NR to end the lull and create interest/momentum for a sp that wants to go up and is begging for a little encougagment - however the NR never comes. I believe that even if there is nothing material right now to announce, we should still have a preliminary NR announcing that Aristotle will be announced lets say mid March and here is what management is doing - then list the planned PR efforts, google enhancements, the planned announcments of minor/major affiliations/collaborations, large healthcare and workplace employer status, how funds will be spent for actual marketing/commercialization, update on Richmond lab, hint of how many covid tests are being completed, actual staff hired, insight to Q4 revenue etc etc etc. This would make for a very nice update and calm the unrest, connect with the shareholder and boost the sp enormously. Some will say this info is already available if you dig around in various forums - truth is we shouldn't have to! I am hopeful that we will see an NR this week because we are really overdue.
We are all sitting on a winner here which I believe will eventually suceed enromously - however, there are better ways toget it moving in the interim.